This transmission electron microscope image shows SARS-CoV-2, the virus that causes Covid-19. Credit: NIAID-RML.

Electronic Data Capture (EDC) systems provider ClinCapture and biopharmaceutical firm MediciNova have formed a strategic collaboration aimed at Covid-19 research.

Last month, after the World Health Organization (WHO) confirmed more than 100,000 cases of global coronavirus cases, ClinCapture CEO Scott Weidley has expanded the philanthropic Weidley’s Wish programme, making it possible for those who are working on the advancement of Covid-19 research to freely access Captivate EDC.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Weidley’s Wish programme normally provides EDC to non-profit organisations, which are involved in conducting clinical trials of rare and orphan diseases.

Using Captivate EDC, companies receive the benefits of private cloud and modern user-interface (UI).

ClinCapture CEO Scott Weidley said: “We are excited to support MediciNova in this critical research. We are thankful that we were able to get this initiative started early, as awareness has grown dramatically.”

MediciNova will be using Captivate EDC to perform a clinical trial targeting severe Covid-19.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of plans to advance its research with the company’s investigational drug ibudilast (MN-166), MediciNova intends to target patients identified with acute respiratory distress syndrome (ARDS) associated with Covid-19.

Ibudilast is an oral, small-molecule inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE) -4 and -10. It inhibits pro-inflammatory cytokines and promotes neurotrophic factors.

In previous studies, the drug candidate led to a significant decrease in serum MIF level.

MediciNova president and CEO Yuichi Iwaki said: “We are very pleased to announce the initiation of a clinical trial of MN-166 in ARDS caused by Covid-19.”

The two companies will perform research using ClinCapture’s Captivate EDC.

Together, ClinCapture and MediciNova hope to advance medical research in finding a treatment for the prevention of acute respiratory distress syndrome.